LIVE

€2.99 ▲+0.87%

/Ascended Heroes/Medicham

Variants

MARGINAL · Conviction 5/10

Medicham

Ascended Heroes · #241 · Illustration Rare

Live NM ask

€2.99

↓ 10.6% 30D

PSA 9

€0.00

USD source

PSA 10

€113.74

USD source

Composite

4.5

Confidence 5/10

4.5

Verify externally — possibly stale

View listing →View price reference →

Buy range€4.55 – €5.95Suspect — verify variant

All prices and projections are for Near Mint English-language cards. Other conditions and languages may vary significantly.

Price history

Ungraded NM PSA 9 PSA 10

Investment thesis

Sub-score breakdown · ROI projections

4.5

SCORE / 10

Liquidity

10.0

Scarcity

9.8

Era potential

5.6

Friction

5.5

Hold-Raw · 5Y Outlook▲ PRIMARY

+•••%

Available with Pro

Grade or sell · per-card

Free account

See if grading this card pays.

How is this scored?

The composite score (0–10) blends signals across trust, set tier, era, liquidity, and price. The four sub-scores shown above (Liquidity, Scarcity, Era CAGR, Friction) describe each card across complementary axes; they share inputs with the composite but use different formulas. The Friction sub-score (added 2026-05-11) combines liquidity, price-spread stability, era maturity, and affordability minus a flat marketplace-fee proxy. The era-benchmark ROI numbers project returns based on the card's release era — they're not card-specific predictions. Limitations: the score is a relative ranking heuristic, not a forecast. Prices are snapshots and can drift between refreshes — always verify externally before buying.

Pop report

PSA 10 gem rate 72.84%Total population

PSA 10

169

PSA 9

PSA 8

Total graded

232

Gem rate 72.84%. Consistent with modern era gem rates; expect supply to grow as more are graded.

OVERVIEW

Investment summary

Ascended Heroes's Medicham (#241) currently trades at €2.99 in the raw market. Its 30-day price movement has declined (-10.6%). By market value it ranks #54 of 295 in Ascended Heroes — the 80th percentile of the set. With recent sales tracked over the trailing 180 days, liquidity is rated high. Read together, a upper-tier ranking in Ascended Heroes alongside softening 30-day momentum frames where Medicham sits in the set's pricing structure — context worth weighing against the set's stronger names before timing an entry. Market data is informational only and does not constitute investment advice.